Day One Biopharmaceuticals Board Recommends Tender Offer for Servier Acquisition at $21.50 Per Share

summarizeSummary

Day One Biopharmaceuticals' board has recommended shareholders accept Servier's $2.5 billion all-cash acquisition offer of $21.50 per share, representing a significant premium.

check_boxKey Events

• Board Recommends Acquisition

  Day One Biopharmaceuticals' Board of Directors has formally recommended shareholders tender their shares in response to Servier's acquisition offer.

• Acquisition Price and Premium

  Servier will acquire Day One for $21.50 per share in cash, representing a premium of approximately 68% over Day One's closing price on March 5, 2026.

• Total Equity Value

  The transaction values Day One's total equity at approximately $2.5 billion.

• Expected Closing

  The acquisition is anticipated to close in the second quarter of 2026, pending regulatory approvals and other customary conditions.

auto_awesomeAnalysis

Day One Biopharmaceuticals' Board of Directors has formally recommended that shareholders accept Servier's tender offer to acquire all outstanding shares for $21.50 in cash. This acquisition, valued at approximately $2.5 billion, represents a substantial premium of about 68% over Day One's closing price on March 5, 2026. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions including U.S. antitrust clearance and the tender of a majority of outstanding shares. This definitive agreement marks a significant positive outcome for Day One shareholders, fundamentally altering the company's future as it integrates into Servier's rare oncology portfolio.